Malaria antigens and methods of use
The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.
1. A composition comprising a pharmaceutically acceptable carrier and one or more isolated polypeptides, wherein each of the one or more polypeptides comprises the amino acid sequence of SEQ ID NO: 98, SEQ ID NO: 99, or SEQ ID NO: 100.
2. A composition comprising a pharmaceutically acceptable carrier and one or more isolated nucleic acid sequences, wherein each of the one or more nucleic acid sequences encodes a polypeptide comprising the amino acid sequence of any one of SEQ ID NO: 98-SEQ ID NO: 100.
3. The composition of claim 2 , which comprises the isolated nucleic acid sequence of SEQ ID NO: 101 or SEQ ID NO: 103.
4. The composition of claim 2 , wherein the one or more isolated nucleic acid sequences are present in a vector.
5. The composition of claim 4 , wherein the vector is an adenoviral vector.
6. The composition of claim 5 , wherein the adenoviral vector is a human adenoviral vector or a gorilla adenoviral vector.
7. The composition of claim 5 , wherein the adenoviral vector requires complementation of a deficiency in one or more early regions of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
8. The composition of claim 7 , wherein the one or more early regions are selected from the group consisting of the E1 region, the E2 region, and the E4 region of the adenovirus genome.
9. The composition of claim 7 , wherein the adenoviral vector requires complementation of a deficiency in the E1 region of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
10. The composition of claim 7 , wherein the adenoviral vector requires complementation of a deficiency in the E1A region or the E1B region of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
11. The composition of claim 7 , wherein the adenoviral vector requires at most complementation of a deficiency in the E4 region of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
12. The composition of claim 7 , wherein the adenoviral vector requires complementation of a deficiency in the E1 region of the adenoviral genome and a deficiency in the E4 region of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
13. A method of inducing a protective immune response against a Plasmodium parasite in a mammal, which method comprises administering to the mammal the composition of claim 1 , whereupon a protective immune response against the Plasmodium parasite in the mammal is induced.
14. The method of claim 13 , wherein the mammal is a human.
15. The method of claim 13 , wherein the Plasmodium parasite is Plasmodium falciparum or Plasmodium vivax.
16. The composition of claim 1 , wherein the composition comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 98.
17. The composition of claim 1 , wherein the composition comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 99.
18. The composition of claim 1 , wherein the composition comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 100.
19. The composition of claim 1 , wherein the one or more polypeptides comprise the amino acid sequences of SEQ ID NO: 98, SEQ ID NO: 99, and SEQ ID NO: 100.